FDA Accepts NDA For Schering-Plough Antipsychotic Asenapine
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering’s acquisition of asenapine developer Organon was completed Nov. 19; Dutch firm has previously reported positive data in comparison to J&J’s Risperdal and Lilly’s Zyprexa.